open access

Vol 6, No 2 (2004)
Published online: 2004-06-02
Get Citation

Enoxaparin in the treatment of chronic limb ischaemia in patients with 200 m claudication — pilot study

Krzysztof Ziaja, Grzegorz Biolik, Wacław Kuczmik, Arkadiusz Krupowies, Marcin Kucharzewski, Damian Ziaja, Michał Glanowski, Tomasz Urbanek, Przemysław Nowakowski, Marek Błaszczyński, Zbigniew Markiel
Chirurgia Polska 2004;6(2):75-82.

open access

Vol 6, No 2 (2004)
Published online: 2004-06-02

Abstract

Background: Our paper is a pilot study of the usefulness of enoxaparin in the treatment of patients with 50–200 m claudication (2-nd degree of Fontaine classification). This is a multicenter, randomized and open investigation.
Material and methods: An initial observation was performed on a group of 21 patients consisting of 17 males and 4 females, aged between 46 and 69. The study group was divided into two subgroups due to the type of treatment administered. The first subgroup consisted of 18 patients receiving a daily dosage of enoxaparin subcutaneously established in accordance with their body mass index. Additionally the treatment of all patients in this group was reinforced with 600 mg of pentoxyfilin and 500 mg of xantionle nicotinate in one oral daily dosage. Both agents were in prolonged forms. In the second group there were 3 patients (2 male and 1 female) who received only 600 mg of pentoxyfilin and 500 mg of xantinol nicotinate in one oral daily dosage.
Results: Of the 21 patient group, 14 patents underwent a full period of observation (66%). A subjective improvement of blood supply in lower extremities, elongation of claudication, was observed in 13 patients. After the 90 day observation period the treatment resulted in the elongation of claudication from 10 to 300 meters.
Conclusions: 1. The employment of enoxaparin as an adjuvant treatment in individually specified daily dosage in patients with peripheral arterial occlusive disease has a positive therapeutic efficacy in stage II of Fontaine classification. 2. The improvement of peripheral microcirculation condition by the inhibition (blockage) of the clotting cascade at the level of activated factor X (Xa) seems to be the next step in the effective treatment of peripheral arterial occlusive disease.

Abstract

Background: Our paper is a pilot study of the usefulness of enoxaparin in the treatment of patients with 50–200 m claudication (2-nd degree of Fontaine classification). This is a multicenter, randomized and open investigation.
Material and methods: An initial observation was performed on a group of 21 patients consisting of 17 males and 4 females, aged between 46 and 69. The study group was divided into two subgroups due to the type of treatment administered. The first subgroup consisted of 18 patients receiving a daily dosage of enoxaparin subcutaneously established in accordance with their body mass index. Additionally the treatment of all patients in this group was reinforced with 600 mg of pentoxyfilin and 500 mg of xantionle nicotinate in one oral daily dosage. Both agents were in prolonged forms. In the second group there were 3 patients (2 male and 1 female) who received only 600 mg of pentoxyfilin and 500 mg of xantinol nicotinate in one oral daily dosage.
Results: Of the 21 patient group, 14 patents underwent a full period of observation (66%). A subjective improvement of blood supply in lower extremities, elongation of claudication, was observed in 13 patients. After the 90 day observation period the treatment resulted in the elongation of claudication from 10 to 300 meters.
Conclusions: 1. The employment of enoxaparin as an adjuvant treatment in individually specified daily dosage in patients with peripheral arterial occlusive disease has a positive therapeutic efficacy in stage II of Fontaine classification. 2. The improvement of peripheral microcirculation condition by the inhibition (blockage) of the clotting cascade at the level of activated factor X (Xa) seems to be the next step in the effective treatment of peripheral arterial occlusive disease.
Get Citation

Keywords

enoxaparin; pentoxyfilin; xanthinol nicotinate; claudication; arteriosclerosis obliterans of lower extremities; treatment; Low Molecular Weight Heparin (LMWH); Unfractioned Heparin (UFH); acetylosalicylic acid (ASA)

About this article
Title

Enoxaparin in the treatment of chronic limb ischaemia in patients with 200 m claudication — pilot study

Journal

Chirurgia Polska (Polish Surgery)

Issue

Vol 6, No 2 (2004)

Pages

75-82

Published online

2004-06-02

Bibliographic record

Chirurgia Polska 2004;6(2):75-82.

Keywords

enoxaparin
pentoxyfilin
xanthinol nicotinate
claudication
arteriosclerosis obliterans of lower extremities
treatment
Low Molecular Weight Heparin (LMWH)
Unfractioned Heparin (UFH)
acetylosalicylic acid (ASA)

Authors

Krzysztof Ziaja
Grzegorz Biolik
Wacław Kuczmik
Arkadiusz Krupowies
Marcin Kucharzewski
Damian Ziaja
Michał Glanowski
Tomasz Urbanek
Przemysław Nowakowski
Marek Błaszczyński
Zbigniew Markiel

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Via MedicaBy "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl